Specify a stock or a cryptocurrency in the search bar to get a summary
Egetis Therapeutics AB (publ)
EGTXEgetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden. Address: Klara Norra Kyrkogata 26, Stockholm, Sweden, 111 22
Analytics
WallStreet Target Price
137.62 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures EGTX
Dividend Analytics EGTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History EGTX
Stock Valuation EGTX
Financials EGTX
Results | 2019 | Dynamics |